Keros Therapeutics (NASDAQ:KROS) Reaches New 1-Year Low – Should You Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS) shares hit a new 52-week low on Wednesday . The company traded as low as $15.18 and last traded at $15.18, with a volume of 167623 shares. The stock had previously closed at $15.84.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Guggenheim cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Wells Fargo & Company raised their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Scotiabank dropped their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday, December 13th. Finally, William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Keros Therapeutics Stock Performance

The stock has a market capitalization of $606.39 million, a P/E ratio of -2.87 and a beta of 1.43. The firm has a fifty day moving average price of $44.38 and a two-hundred day moving average price of $48.99.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the company posted ($1.33) earnings per share. On average, research analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics in the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Keros Therapeutics in the second quarter worth about $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the third quarter worth about $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.